Skip to main content
Fig. 4 | BMC Health Services Research

Fig. 4

From: Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan

Fig. 4

Multivariable logistic regression analysis for National Health Insurance price revisions. Factors were selected by stepwise method (variable increase/decrease method, threshold: p < 0.25). Test for the whole model: p < 0.001, R2 = 0.4358. Compound type is classified into molecularly targeted drug, hormonal drug, antibody, cytotoxic drug, immunotherapy drug and other. Additional indication is classified into yes (with additional indication) and no (no additional indication). Initial indication is classified into rare cancer, minor cancer and major cancer. NHI: National Health Insurance

Back to article page